Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
Article Details
- CitationCopy to clipboard
Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK
Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):417-8.
- PubMed ID
- 11927504 [ View in PubMed]
- Abstract
Not Available